UPJOINT: Upadacitinib Demonstrates Efficacy, Safety in Interim Analysis
An interim analysis from the UPJOINT trial provides insight into the effects of upadacitinib use in real-world settings among patients with oligo- or polyarticular psoriatic arthritis.
Source: hcplive.com